Gavi’s Annual Progress Report highlights rebound in routine immunisation underpinned by record domestic funding; warns of challenges ahead
Gavi’s Annual Progress Report highlights rebound in routine immunisation underpinned by record domestic funding; warns of challenges ahead
1 November 2023
A father and child in Kabul, Afghanistan. Credit: Gavi/2023/Oriane Zerah.
Gavi reveals that basic childhood immunisation rebounded in 2022 as lower-income countries collectively contributed US$ 162 million to co-finance Gavi-supported vaccines, the highest amount in their 23-year history.
In its latest Annual Progress Report, Gavi reveals that basic childhood immunisation rebounded in 2022 as lower-income countries collectively contributed US$ 162 million to co-finance Gavi-supported vaccines, the highest amount in their 23-year history. This brings the total amount contributed by lower-income countries since 2008 – when country co-financing began – to US$ 1.5 billion.
According to the report, despite a period of economic turbulence, with the exception of three waivers due to humanitarian crises, all Gavi-supported countries met their vaccine co-financing targets in 2022.
“Gavi-supported countries have made a huge effort to restore immunisation, broaden coverage, and mobilise domestic resources for long-term sustainability,” said José Manuel Barroso, Chair of the Gavi Board. “The prospect for immunisation to deliver transformative societal and economic benefits is greater than ever, but only if we are collectively able to navigate the path ahead.”
The report notes the economic returns from vaccination itself: immunisation programmes in lower-income countries supported by Gavi have generated more than US$ 220.5 billion in economic benefits since 2000.
Alongside positive news, the progress report notes several challenges lower-income countries face looking ahead. Routine immunisation coverage in Gavi implementing countries remains 2% lower than in 2019, the last year before the pandemic emerged to disrupt gains made. In addition, progress across countries and regions is uneven.
And while the number of zero-dose children (those who have not received a single vaccine shot) dropped to 10.2 million in 2022, it is still higher than the estimated 9 million there were in 2019.
Read the complete Gavi Annual Progress Report 2022
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.